BTG INTL
SpecialtyBTG INTL is a specialty pharmaceutical company focused on Cardiovascular, Gastroenterology. Key products include VISTOGARD.
BTG INTL's Key Drugs
BTG INTL's core commercial portfolio centers on VISTOGARD, AURLUMYN, XURIDEN, spanning Cardiovascular and Gastroenterology — its most strategically important drugs approved in the last 15 years.
BTG INTL's Recent FDA Approvals
New NDA/BLA approvals for BTG INTL over the last two years — novel drugs only, excluding generics and label supplements.
BTG INTL's Therapeutic Areas
BTG INTL's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Gastroenterology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BTG INTL's Top Competitors
BTG INTL's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Takeda, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BTG INTL Pipeline Snapshot
Active clinical trials for BTG INTL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VISTOGARD leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling